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Introduction: The aim of this study was to validate a molecular 
expression signature [cell cycle progression (CCP) score] that 
identifies patients with a higher risk of cancer-related death after 
surgical resection of early stage (I-II) lung adenocarcinoma in 
a large patient cohort and evaluate the effectiveness of combin-
ing CCP score and pathological stage for predicting lung cancer 
mortality.
Methods: Formalin-fixed paraffin-embedded surgical tumor samples 
from 650 patients diagnosed with stage I and II adenocarcinoma who 
underwent definitive surgical treatment without adjuvant chemother-
apy were analyzed for 31 proliferation genes by quantitative real-
time polymerase chain reaction. The prognostic discrimination of the 
expression score was assessed by Cox proportional hazards analysis 
using 5-year lung cancer-specific death as primary outcome.
Results: The CCP score was a significant predictor of lung cancer-
specific mortality above clinical covariates [hazard ratio (HR) = 1.46 
per interquartile range (95% confidence interval = 1.12–1.90; 
p = 0.0050)]. The prognostic score, a combination of CCP score and 
pathological stage, was a more significant indicator of lung cancer 
mortality risk than pathological stage in the full cohort (HR = 2.01; 
p = 2.8 × 10−11) and in stage I patients (HR = 1.67; p = 0.00027). 
Using the 85th percentile of the prognostic score as a threshold, there 
was a significant difference in lung cancer survival between low-risk 
and high-risk patient groups (p = 3.8 × 10−7).
Conclusions: This study validates the CCP score and the prognos-
tic score as independent predictors of lung cancer death in patients 
with early stage lung adenocarcinoma treated with surgery alone. 
Patients with resected stage I lung adenocarcinoma and a high prog-
nostic score may be candidates for adjuvant therapy to reduce cancer-
related mortality.
Key Words: Carcinoma, Nonsmall cell lung cancer, Real-time poly-
merase chain reaction, Risk stratification.
(J Thorac Oncol. 2015;10: 67–73)
Lung cancer is one of the most common cancers in the United States and Europe and the leading cause of can-
cer death for both men and women in the United States, with 
approximately 160,000 patient deaths per year. Nonsmall cell 
lung cancer (NSCLC) comprises 85% of lung cancer cases 
of which up to 40% have adenocarcinoma histology. Patients 
diagnosed with stage I and II adenocarcinoma (localized dis-
ease) have 5-year overall mortality rates ranging from 30% in 
stage IA, 50% in stage IB disease, and up to 66% in stage II.1,2
The results of the Lung Adjuvant Cisplatin Evaluation 
meta-analysis established surgical resection followed by adju-
vant chemotherapy with a cisplatin doublet as standard of care 
in patients with stage II and III disease.3–5 However, this analy-
sis failed to demonstrate a significant benefit for patients with 
stage IA and IB disease. A separate study, CALGB 9633, com-
prised of patients with stage IB disease, demonstrated a statis-
tically significant survival advantage for patients with tumors 
≥4 cm who received adjuvant therapy.6 The significant mortality 
rate from lung cancer at 5 years for patients with stage I disease 
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despite complete surgical resection suggests that some patients 
may benefit from adjuvant chemotherapy although molecular 
markers to identify those patients are lacking.1,7
Defining the population at high risk of recurrence will 
allow for rational clinical trials that will determine the best 
therapies for these patients. There is a particularly acute need 
currently for developing such a strategy as the recent introduc-
tion of low-dose computed tomographic scans or other screen-
ing modalities for high-risk populations will lead to increased 
numbers of patients with early stage disease.8 The ability 
to identify those patients with a high rate of recurrence, for 
whom adjuvant chemotherapy might provide benefit, is cru-
cial in reducing the mortality from NSCLC. The fundamental 
role of this strategy is to identify which patients with early 
stage lung adenocarcinoma should be subjected to the risk of 
adjuvant therapy and which are unlikely to benefit from it.
Molecular signatures have been developed to assist in 
defining the risk of death with early stage disease.9–12 However, 
a recent review highlighted the unsolved issues in the devel-
opment and analysis of gene signatures in general, and lung 
cancer signatures in particular.13 Very few of these signatures 
have been rigorously tested in combination with pathological 
variables, and even fewer have been applied to formalin-fixed 
clinical samples. Currently, no gene signatures have been 
included in clinical practice guidelines for the treatment of 
early stage resectable lung cancer.
We previously described the development and validation 
of an RNA expression signature based on cell cycle progression 
(CCP) genes to predict death from lung cancer.14 In that analy-
sis, the CCP score was a highly significant, independent pre-
dictor of cancer-specific mortality in adenocarcinomas in three 
independent datasets. Pathological stage remained an indepen-
dent prognostic factor besides the CCP score, which prompted 
us to model a combined prognostic score of CCP and patho-
logical stage based on the data in the CCP validation study. The 
combined score integrated molecular and clinical data to obtain 
a superior predictor of outcome than either variable alone.
The purpose of this study was to further validate the 
association of CCP with 5-year lung cancer mortality after 
adjusting for clinical parameters. We also sought to investi-
gate the prognostic score as a predictor of 5-year lung can-
cer mortality risk and to establish a cut point for classifying 
patients into low- and high-risk groups. This study validates 
the CCP and prognostic score as robust molecular markers 
that predict death from early stage adenocarcinoma and pro-
vide useful information to determine which patients need to 
be considered for additional therapy to improve survival.
MATERIALS AND METHODS
Patients
Samples for this study were collected from consecutive 
population cohorts surgically treated at Brigham and Women’s 
Hospital (BWH; Boston, MA) and the Royal Infirmary of 
Edinburgh (RIE; Edinburgh, United Kingdom) with appropriate 
Institutional Review Board approvals. Inclusion criteria were 
patients with NSCLC with adenocarcinoma histology, stage 
I-II disease according to 7th edition International Association 
for the Study of Lung Cancer (IASLC) guidelines, complete 
resection of the primary tumor, no treatment with radiation or 
chemotherapy before surgery, no adjuvant treatment with radia-
tion or chemotherapy within 12 weeks of surgery, and at least 
1-month of follow up. Patients diagnosed with previous lung can-
cer or synchronous lung cancers were excluded. Adenocarcinoma 
subtypes were assessed in the BWH cohort and are provided in 
Supplemental Table 1 (Supplemental Digital Content 1, http://
links.lww.com/JTO/A710). To ascertain the primary outcome 
measure of death from lung cancer, clinical records or death 
records and ICD-10 codes were retrieved and reviewed. The sec-
ondary outcome measure was overall survival.
BWH provided 655 samples. Twelve samples were 
excluded based on little/no tumor or incorrect tumor pathol-
ogy. The majority of samples (641/655) generated passing 
molecular scores but only 474 samples matched the above 
selection criteria, had complete clinical data and passing 
molecular scores. All samples were reviewed by a pulmonary 
pathologist to confirm diagnosis and tumor content before 
being sent for molecular analysis. Of 205 eligible samples 
from the RIE, 190 (92.6%) had passing molecular scores and 
176 samples conformed to all inclusion criteria and had full 
clinical data. This study was conducted and reported accord-
ing to REMARK guidelines.15 All samples were rendered non-
identifiable so that all laboratory analysis was blinded to any 
clinical or pathological data.
Expression Assay
All assay procedures were fully developed before ini-
tiation of the validation study and implemented in a Clinical 
Laboratory Improvement Amendments (CLIA) certified 
laboratory. Experimental details of the CCP score have been 
described.14 Briefly, tumor tissue was marked on a hematoxylin 
and eosin-stained section of formalin-fixed paraffin-embedded 
(FFPE) samples by a pathologist and two 5 to 10 μm sections 
of tumor tissues were excised by macro-dissection. Tissue was 
pooled and total RNA extracted with the FFPE miRNEasy 
Kit (Qiagen, Valencia, CA). RNA yield was determined using 
a Nanodrop 2000 Spectrophotometer (ThermoScientific, 
Waltham, MA) and RNA quality was assessed by the expres-
sion as described in the passing criteria below; 500 ng of total 
RNA were DNase-treated (Sigma-Aldrich, St. Louis, MO) and 
reverse transcribed with the High Capacity cDNA Archive Kit 
(Life Sciences, Foster City, CA). For pre-amplification, 60 ng 
of RNA-equivalent cDNA and a multiplex of all gene prim-
ers were setup in triplicate polymerase chain reaction (PCR) 
reactions. After 14 cycles, preamplified material was diluted 
1:20 and used to inoculate custom Taqman Low Density arrays 
(Life Technologies, Grand Island, NY). Expression levels of 15 
housekeeping genes and 31 cell cycle target genes were quanti-
fied as Ct values at a predefined threshold. Passing criteria for 
calculation of CCP scores included amplification of a mini-
mum of 13 housekeeping genes and 22 cell cycle genes with 
measurable raw Ct values and a standard deviation of less than 
0.5 between CCP scores from the three replicates for each sam-
ple. A list of genes that constitute the CCP score is provided in 
Supplemental Table 2 (Supplemental Digital Content 1, http://
links.lww.com/JTO/A710).
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Determination of the CCP Score 
and the Prognostic Score
Details of the selection and verification of the CCP 
score in lung adenocarcinoma have been previously pub-
lished.14 In summary, the CCP score is the unweighted aver-
age of 31 cell cycle genes normalized by the average of 15 
housekeeping genes. Each unit of the CCP score represents a 
twofold change in mRNA expression. The algorithm for the 
prognostic score was developed in an independent training 
cohort and fully defined before analysis. Details on the deriva-
tion of the coefficients in the prognostic score are provided in 
the Supplemental Methods (Supplemental Digital Content 1, 
http://links.lww.com/JTO/A710). In summary, the coefficients 
for the CCP score and pathological stage were determined 
from a Cox proportional hazard (PH) model of the CCP score 
and pathological stage in three cohorts from the CCP valida-
tion study.14 The resulting score is scaled and shifted to yield 
the final equation which is prognostic score = 20 × (0.33 × 
CCP + 0.52 × Stage) + 15 where the CCP score was rounded 
to the nearest 10th and the prognostic score was rounded to the 
nearest integer. Calculation of the prognostic score was fixed 
before the analysis presented here.
Statistical Analysis
Statistical analysis was performed only after all patient 
clinical data and expression data had been independently 
completed. Primary outcome for all analyses was death from 
lung cancer within 5 years of surgery. Follow-up times started 
on the date of surgery. Patients who were lost to follow up, 
died from other causes, or died from unknown causes without 
evidence of lung cancer recurrence were censored at the last 
observation. Deaths attributed to lung cancer, and deaths due 
to unknown causes after lung cancer recurrence were consid-
ered events. All patients were censored at 5 years.
The contribution of the CCP score and clinical variables 
to the prediction of outcome was assessed in univariate and 
multivariate models using Cox PH regression. Gender and 
pleural invasion were modeled as binary variables. Age, tumor 
size (rounded to the nearest millimeter), the CCP score, and 
the prognostic score were included as quantitative covariates. 
Pathological stage and cohort were handled as four-level (IA, 
IB, IIA, and IIB) and two-level (BWH and RIE) categorical 
variables, respectively. Cox PH p-values were based on the 
chi-squared test statistics from partial likelihood models. 
Analyses were conducted using R version 2.15.1.16 A p-value 
less than 0.05 was considered a significant result. All reported 
p-values are two-sided. Hazard ratios (HR) for CCP and prog-
nostic score are reported per interquartile range.
Univariate Cox PH analysis tested the association of 
the prognostic score with 5-year lung cancer mortality. We 
estimated the risk of lung cancer death within 5 years of 
resection, as a function of the prognostic score, according 
to this univariate model; 95% confidence intervals (CI) for 
risk estimates were calculated based on the log hazard. To 
evaluate the significance of the prognostic score compared 
with pathological stage alone, a bivariate model of prognos-
tic score and stage was compared with a model with patho-
logical stage alone.
We predefined a threshold for categorizing low and high 
risk as the 85th percentile of the prognostic score in stage IA 
patients. This threshold was chosen based on literature show-
ing that approximately 15% of stage IA patients died from 
lung cancer within 5 years.14,17–21 Patients at or below the cut 
point were classified as low risk; patients with prognostic 
score above were high risk. Using the Mantel–Cox log-rank 
test, with the prognostic score coded as a binary variable, we 
tested the hypothesis that the rate of 5-year lung cancer mor-
tality would be significantly less in the low prognostic score 
group than in the high prognostic score group.
RESULTS
To validate the CCP score and the prognostic score as 
predictors of outcome in lung adenocarcinoma, we assembled 
a cohort of surgically treated, chemotherapy and radiation-
naive stage I and II patients. The validation set included 650 
patients from two datasets: 474 patients from the BWH and 
176 patients from the RIE. Patient clinical and pathological 
features are shown in Table 1. The 5-year lung cancer survival 
rate was 73% with a median follow up of 5.5 years for patients 
who did not die of lung cancer.
Validation of the CCP Score as an Independent 
Predictor of Cancer-specific Mortality
The primary goal of the study was to validate the CCP 
score as an independent prognostic marker in the presence of 
clinicopathological parameters, thus justifying its combination 
with pathological stage in the prognostic score. In this analy-
sis, the CCP score was a significant predictor of 5-year lung 
cancer-specific mortality after adjustment for clinical variables 
(Table 2). The CCP score was highly significant in univariate 
analysis [HR = 1.79 (95% CI = 1.42–2.27; p = 1.1 × 10−6)]. 
Age (p = 0.0097), gender (with decreased mortality for female 
patients; p = 0.0091), pathological stage (p = 7.7 × 10−9), and 
tumor size (p = 1.1 × 10−5) were also significant factors in 
TABLE 1.  Patient Clinical and Pathological Characteristics
BWH
N = 474
n (%)
RIE
N = 176
n (%)
Age at diagnosis (Median ± SD) 67 ± 11 68 ± 10
Gender Male 172 (36) 69 (39)
Female 302 (64) 107 (61)
Tumor size <3 cm 394 (83) 76 (43)
≥3 cm 80 (17) 100 (57)
Stage IA 309 (65) 36 (20)
IB 142 (30) 53 (30)
IIA 15 (3) 62 (35)
IIB 8 (2) 25 (14)
Pleural invasiona Yes 114 (24) 64 (36)
No 343 (72) 112 (64)
Disease-related death at 5 yrs Yes 92 (19) 60 (34)
No 382 (81) 116 (66)
aPleural invasion data not available for 17 patients.
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predicting the risk of cancer-related death. There was a signifi-
cant difference in mortality between the two patient cohorts 
(p = 0.00092). This difference was expected given the larger 
proportion of stage II patients in the RIE dataset; there was 
no longer a significant difference after adjusting for stage. In 
multivariate analysis, the CCP score was an independent risk 
factor for lung cancer mortality (p = 0.0050) with a HR of 
1.46 (95% CI = 1.12–1.90). Apart from the CCP score, only 
stage (p = 0.0023) and age (p = 0.010) remained significant 
predictors of disease-specific mortality in multivariate anal-
ysis. Results for overall survival were comparable with the 
addition of age remaining a significant predictor in multi-
variate analysis (Supplemental Table 4, Supplemental Digital 
Content 1, http://links.lww.com/JTO/A710).
Similar results were obtained when the analysis was 
restricted to stage I patients. CCP score, age, gender, patho-
logical stage, tumor size, and pleural invasion were signifi-
cant in univariate analysis (Table 3). In multivariate analysis 
TABLE 2.  Univariate and Multivariate Cox Proportional Hazards Analysis of CCP Score and Other Parameters in all Patientsc
Univariate Multivariate
HR (95% CI) p Value HR (95% CI) p Value
CCPa 1.79 (1.42–2.27) 1.1 × 10−6 1.46 (1.12–1.90) 0.0050
Age 1.02 (1.00–1.04) 0.0097 1.02 (1.01–1.04) 0.010
Gender 0.0091 0.064
  Male 1 1
  Female 0.65 (0.47–0.90) 0.73 (0.53–1.02)
Stage 7.7 × 10−9 0.0023
  IA 1 1
  IB 1.65 (1.11–2.44) 1.72 (1.00–2.96)
  IIA 3.79 (2.47–5.75) 3.47 (1.84–6.5)
  IIB 3.30 (1.76–5.77) 3.42 (1.28–8.62)
Tumor sizeb 1.20 (1.11–1.29) 1.1 × 10−5 1.01 (0.88–1.15) 0.93
Pleural invasion 1.30 (0.91–1.82) 0.14 0.83 (0.53–1.29) 0.41
Cohort 0.00092 0.47
  BWH 1 1
  RIE 1.76 (1.26–2.43) 0.86 (0.56–1.3)
aHazard ratio per interquartile range of the CCP score.
bHazard ratio per cm, rounded to the nearest mm.
cEvents/N = 147/633 for multivariate analysis, and univariate analysis of pleural invasion. Other univariate analyses had Events/N = 152/650.
TABLE 3.  Univariate and Multivariate Cox PH Analysis of CCP Score and Other Parameters in Stage IA-IB Patientsb
Univariate Multivariate
HR (95% CI) p Value HR (95% CI) p Value
CCPa 1.63 (1.21–2.20) 0.0013 1.56 (1.12–2.18) 0.0087
Age 1.03 (1.01–1.05) 0.0014 1.03 (1.01–1.05) 0.0087
Gender 0.073 0.13
  Male 1 1
  Female 0.69 (0.47–1.03) 0.73 (0.49–1.1)
Stage 0.012 0.98
  IA 1 1
  IB 1.65 (1.12–2.44) 1.01 (0.42–2.38)
Tumor size 1.24 (1.02–1.48) 0.031 1.15 (0.86–1.53) 0.33
Pleural invasion 0.033 0.41
  No 1 1
  Yes 1.59 (1.04–2.39) 1.38 (0.65–3.03)
Cohort 0.58 0.56
  BWH 1 1
  RIE 1.15 (0.69–1.84) 0.86 (0.49–1.43)
aHR for CCP is per interquartile rang of the CCP score in stage IA-IB patients.
bEvents/N = 96/523 for multivariate analysis, and univariate analysis of pleural invasion. Other univariate analyses had Events/N = 101/540.
71Copyright © 2014 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 10, Number 1, January 2015 Molecular Stratification of Early Stage Lung Cancer
of stage I patients, only the CCP score [HR = 1.56 (95% 
CI = 1.12–2.18; p = 0.0087)] and age (p = 0.0087) were inde-
pendent prognostic factors.
Validation of the Prognostic Score
We next examined the prognostic significance of the 
prognostic score, specifically the added prognostic value over 
pathological stage alone. For this analysis, we employed a 
bivariate Cox PH model with stage and the prognostic score. As 
shown in Table 4, stage alone is a highly significant predictor of 
disease-specific mortality (p = 7.7 × 10−9). However, the value of 
the prognostic score in univariate analysis exceeds that of stage 
by two orders of magnitude [HR = 2.01 (95% CI = 1.64–2.45; 
p = 2.8 × 10−11)] reflecting the prognostic information added 
by the CCP component. This is also manifested in bivariate 
analysis, where the prognostic score remains highly significant 
[HR = 1.86 (95% CI = 1.16–2.97; p = 0.0093)] after adjustment 
for pathological stage, indicating that the molecular part of the 
prognostic score substantially improves its prognostic value 
compared with stage alone. The lack of significance for patho-
logical stage in the bivariate analysis indicates that the coeffi-
cients in the calculation of the prognostic score are appropriate.
In a subanalysis of stage I patients, the prognostic score 
was a more significant predictor of outcome [HR = 1.67 
(95% CI = 1.27–2.20; p = 0.00027)] than pathological stage 
[HR = 1.65 (95% CI = 1.12–2.44; p = 0.012)]. In multivari-
ate analysis, the prognostic score added significant prognostic 
discrimination over pathological stage alone [HR = 1.74 (95% 
CI = 1.16–2.61; p = 0.0080)].
Risk Stratification by the Prognostic Score
The predicted 5-year risk of lung cancer-specific death 
across the range of prognostic score is shown in Figure 1. There 
is also a wide range of prognostic score within each stage cat-
egory and substantial overlap of scores from different stages 
(Figure 1). To demonstrate the effect on patient prognosis of 
adding the CCP score to pathological stage, we compared the 
predicted 5-year risk of disease-specific death by stage alone 
against the prediction obtained from the prognostic score 
(Supplemental Figure 1, Supplemental Digital Conetnt 2, http://
links.lww.com/JTO/A711). Within each stage category, the 
prognostic score provides additional discrimination, changing 
some risk estimates up to threefold. On the basis of the analysis 
of CALGB 9633, dichotomized tumor size can be used as a 
prognostic factor in stage IB patients.6 However, in this dataset, 
tumor size was not a significant prognostic factor in stage IB 
patients [HR = 0.56 (95% CI = 0.28–1.29; p = 0.16)]. In con-
trast, the CCP score does add prognostic discrimination in stage 
1B patients [HR = 1.53 (95% CI = 1.01–2.33; p = 0.044)].
When the predefined threshold was applied to the total 
validation cohort, the cohort separated into almost equal 
groups of patients (low prognostic score, N = 328; high prog-
nostic score, N = 322). Figure 2 shows the Kaplan–Meier-
based survival estimates of low- and high-risk patient groups 
based on prognostic score category. Five-year cancer-specific 
survival in the low-risk group was 82% versus 65% in the 
high-risk group. The difference in survival between the low 
and high patient groups was highly significant (p = 3.8 × 10−7). 
Similar results were obtained in stage I patients (N = 540); 
60.7% of stage I patients fell into the low-risk group with 
5-year cancer-specific survival of 82%. For the 39.3% of high-
risk stage I patients, 5-year survival was 72% (p = 0.0057).
DISCUSSION
These results validate CCP as an independent predictor 
of death from lung adenocarcinoma. In addition, the study vali-
dates the prognostic score as a predictor of survival in early stage, 
surgically resected lung adenocarcinoma. The prognostic score 
combines the CCP score, a highly quantitative molecular assess-
ment of tumor proliferation, with pathological stage, the current 
standard prognostic tool in NSCLC. This approach acknowl-
edges the cooperative nature of molecular and clinical variables. 
TABLE 4.  Prognostic Value of the Prognostic Score and Stage in Univariate and Bivariate Models for Total and Stage I Patients
Total Cohort
Univariate Bivariate
HR (95% CI) p Value HR (95% CI) p Value
Prognostic scorea 2.01 (1.64–2.45) 2.8 × 10−11 1.86 (1.16–2.97) 0.0093
Stage 7.7 × 10−9 0.38
  IA 1 1
  IB 1.65 (1.11–2.44) 1.03 (0.61–1.75)
  IIA 3.79 (2.47–5.75) 1.45 (0.62–3.35)
  IIB 3.30 (1.76–5.77) 0.92 (0.29–2.82)
Stage I patients
Univariate Bivariate
HR (95% CI) p Value HR (95% CI) p Value
Prognostic scorea 1.67 (1.27–2.20) 0.00027 1.74 (1.16–2.61) 0.0080
Stage 0.012 0.80
  IA 1 1
  IB 1.65 (1.12–2.44) 0.93 (0.52–1.66)
aHazard ratio is reported per interquartile range of the prognostic score.
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Many signatures can be shown to add discrimination above that 
provided by clinical variables. Yet, clinical parameters remain 
independently prognostic such that the best discrimination is 
obtained by combining both.7,9 The added prognostic value of the 
molecular component is obtained by examining the information 
from the combined score within each level of the best prognostic 
clinical variable. Specifically, the prognostic score adds discrimi-
nation within each of the early pathological stages. For example, 
patients with stage IA disease based on stage alone would have 
a 15% probability of death at 5 years from his/her disease. A 
prognostic score of 47 in this same patient would translate to a 
42% risk of death from lung cancer at 5 years and may warrant 
a discussion of risks/benefits of adjuvant chemotherapy and/or 
enrollment into a clinical trial of adjuvant therapy.
There were multiple strengths of this study including 
(1) a large patient cohort with associated statistical power, 
(2) a homogenous patient population of stage I and II patients 
without adjuvant treatment, (3) a predefined prognostic score 
and predefined cut-offs for risk categories, (4) specimens col-
lected from two independent centers in the United States and 
Europe, and (5) a validated, quantitative polymerase chain 
reaction-based platform suitable for the analysis of routine 
clinical FFPE specimens. One potential limitation is the 
exclusion of known prognostic pathological features such as 
tumor grade/differentiation and the presence of lymphovas-
cular invasion from the analysis. It is possible that this assay 
is statistically independent from these features, but even if it 
recapitulates them, the test still provides valuable information 
by quantifying these descriptive features and combining the 
data into a more accessible format.
This test provides prognostic information to the patient 
and their physician that can be used in making decisions on 
treatment including whether to have adjuvant chemotherapy, 
plan a more rigorous follow up, or participate in clinical trials. 
This test also provides a way for clinicians conducting chemo-
therapy trials in homogeneous high-risk patient cohorts to quan-
tify effective adjuvant therapy regimens in these patients with 
stage IA and IB lung adenocarcinoma. It has been suggested that 
prospective studies to establish chemotherapy benefit in high-
risk individuals could potentially demonstrate full clinical utility 
of the prognostic score. However, these studies are currently not 
feasible due to the required study size and extended follow-up 
times necessary for endpoints. In lieu of a prospective study, 
chemotherapy benefit and risk of death from therapy, as reported 
in the LACE studies, can be used to calculate benefit in the low - 
and high-risk populations as determined by the prognostic score. 
We expect the high-risk population to receive a significant abso-
lute benefit to chemotherapy, whereas the low-risk population 
will receive little to no absolute benefit to chemotherapy and 
may have an increase in risk of death due to treatment.
In summary, our study shows independent validation of 
a previously described CCP signature to predict death from 
early stage adenocarcinoma. The prognostic score, utilizing 
stage, and CCP, can classify patients into low and high-risk 
A
B
Prognostic Score Stratified by Stage
Pa
tie
nt
s 
(%
)
20 604030 50 7010
0
10
5
15 IA
IB
II
0
20
40
60
80
100
20
40
60
30 50 7010
Prognostic Score
5-
Ye
ar
 L
un
g 
C
an
ce
r M
or
ta
lit
y 
R
is
k 
(%
)
Low Risk
Average: 18% 
(95% CI: 13%−23%)
High Risk
Average: 35%
(95% CI: 30%−41%)
FIGURE 1.  Risk estimates based on the prognostic 
score and the distribution of prognostic score by 
stage. A, Five-year cancer-specific survival estimates 
were derived from a Cox PH model using the con-
tinuous combined prognostic score. The vertical line 
represents the predefined threshold at the 85th per-
centile of the prognostic score in stage IA patients. 
Average risk estimates for the low- and high-risk 
groups are given in the inset. B, The prognostic 
score distribution for patients of different stages 
shows the overlap of prognostic scores between 
stage groups. Low prognostic score stage IB patients 
are grouping with stage IA and high prognostic 
score stage IB patients extend into stage II patients.
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categories to allow for improved treatment selection. The high 
prognostic score group had an average mortality risk that was 
nearly twofold higher than the low prognostic score group. 
With the expected increase in diagnosis of early stage lung 
cancer due to adoption of screening modalities, the prognostic 
score can be used to identify a subset of early stage patients 
who have a high risk for recurrence and for whom adjuvant 
chemotherapy may be more effective.
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FIGURE 2.  Likelihood of lung cancer survival based on prog-
nostic score category for (A) the total cohort and (B) stage I 
patients. Kaplan-Meier survival estimates were derived for low 
prognostic score and high prognostic score patient groups 
based on the predefined prognostic score threshold.
